OpGen’s Acuitas® Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Fa...
June 15 2017 - 3:03PM
OpGen, Inc. (NASDAQ:OPGN) today announced the publication of a
citywide evaluation of Washington, D.C.’s healthcare facilities to
gauge the prevalence of Carbapenem-Resistant Enterobacteriaceae
(CRE) throughout the District of Columbia. OpGen’s
Acuitas DNA tests and Acuitas Lighthouse® bioinformatics were
utilized to test over 1,000 patient samples across 16 institutions,
including eight acute care hospitals, two long-term acute care
hospitals, one inpatient rehabilitation facility, and five skilled
nursing facilities.
The results, published in Infection Control &
Hospital Epidemiology, the journal of the Society for Healthcare
Epidemiology of America (SHEA), revealed the prevalence of CRE, a
family of highly pathogenic antibiotic-resistant organisms, are
endemic across Washington, D.C. healthcare facilities, with 5.2% of
inpatients testing positive for the bacteria. As a result of this
study, healthcare facilities were able to establish a baseline
prevalence of CRE in Washington, D.C., and demonstrate the ability
to work together to identify and prevent future outbreaks of
dangerous antibiotic-resistant organisms.
“This collaborative effort to understand the
prevalence of a CRE across multiple institutions has helped create
awareness of the problem of MDROs in our healthcare facilities,”
said Evan Jones, Chairman and CEO of OpGen. “Our
technology proved to be valuable in both understanding the
epidemiology of CRE and demonstrated that early detection of
threats may provide timely information enabling clinicians to take
the necessary precautions to protect patients and co-workers.”
About OpGen OpGen,
Inc. is harnessing the power of informatics and genomic
analysis to provide complete solutions for patient, hospital and
network-wide infection prevention and treatment. Learn more
at www.opgen.com and
follow OpGen on Twitter and LinkedIn.
OpGen, Acuitas, Acuitas Lighthouse and
QuickFISH are registered trademarks of OpGen, Inc.
Forward-Looking Statements This
press release includes statements relating to the
company's products and services development efforts.
These statements and other statements regarding our future plans
and goals constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, our ability to successfully, timely and
cost-effectively develop, seek regulatory approval for and
commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the success of our commercialization efforts,
the effect on our business of existing and new regulatory
requirements, and other economic and competitive factors. For a
discussion of the most significant risks and uncertainties
associated with OpGen's business, please review our
filings with the Securities and Exchange
Commission (SEC). You are cautioned not to place undue
reliance on these forward-looking statements, which are based on
our expectations as of the date of this press release and speak
only as of the date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor and Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024